Jubilant HollisterStier Enters $149.6M Agreement with U.S. Govt.

SourceContract Pharma
Date Published05/31/2022
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Jubilant HollisterStier LLC
Parent companyJubilant Pharmova Ltd.
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2025
Domestically, the work will be done:In-house
Capital investment ($):285
Country(ies) from which reshored:India
City reshored to:Spokane
State(s) reshored to:WA
If relevant, work nearshored to:-
Product(s) reshoredinjectable filling
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Government Incentives, covid
Government Incentive dollar amount:American Rescue Plan, BARDA
Find Reshoring Articles